Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Debt to Equity (2016 - 2023)

Historic Debt to Equity for Marker Therapeutics (MRKR) over the last 7 years, with Q1 2023 value amounting to $0.01.

  • Marker Therapeutics' Debt to Equity changed N/A to $0.01 in Q1 2023 from the same period last year, while for Mar 2023 it was $0.01, marking a year-over-year change of. This contributed to the annual value of $0.13 for FY2022, which is N/A changed from last year.
  • Per Marker Therapeutics' latest filing, its Debt to Equity stood at $0.01 for Q1 2023.
  • Marker Therapeutics' 5-year Debt to Equity high stood at $0.29 for Q2 2022, and its period low was $0.0 during Q4 2019.
  • Over the past 3 years, Marker Therapeutics' median Debt to Equity value was $0.0 (recorded in 2019), while the average stood at $0.08.
  • The largest annual percentage gain for Marker Therapeutics' Debt to Equity in the last 5 years was 1484.39% (2019), contrasted with its biggest fall of 9826.15% (2019).
  • Marker Therapeutics' Debt to Equity (Quarter) stood at $0.0 in 2019, then soared by 18038.53% to $0.13 in 2022, then tumbled by 95.2% to $0.01 in 2023.
  • Its Debt to Equity stands at $0.01 for Q1 2023, versus $0.13 for Q4 2022 and $0.22 for Q3 2022.